814 related articles for article (PubMed ID: 17522249)
1. Management and preparedness for infusion and hypersensitivity reactions.
Lenz HJ
Oncologist; 2007 May; 12(5):601-9. PubMed ID: 17522249
[TBL] [Abstract][Full Text] [Related]
2. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy.
Chung CH
Oncologist; 2008 Jun; 13(6):725-32. PubMed ID: 18586928
[TBL] [Abstract][Full Text] [Related]
3. [Infusion reactions].
Sato K; Kohgo Y
Gan To Kagaku Ryoho; 2008 Oct; 35(10):1671-4. PubMed ID: 18931569
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents.
Lee C; Gianos M; Klaustermeyer WB
Ann Allergy Asthma Immunol; 2009 Mar; 102(3):179-87; quiz 187-9, 222. PubMed ID: 19354063
[TBL] [Abstract][Full Text] [Related]
5. Are antineoplastic drug acute hypersensitive reactions a submerged or an emergent problem? Experience of the Medical Day Hospital of the Fondazione IRCCS Istituto Nazionale Tumori.
Ferrari LA; Fanetti G; Rossi FG; Brambilla MC; Re B; Buzzoni R
Tumori; 2014; 100(1):9-14. PubMed ID: 24675484
[TBL] [Abstract][Full Text] [Related]
6. Allergic and nonallergic delayed infusion reactions during natalizumab therapy.
Hellwig K; Schimrigk S; Fischer M; Haghikia A; Müller T; Chan A; Gold R
Arch Neurol; 2008 May; 65(5):656-8. PubMed ID: 18474743
[TBL] [Abstract][Full Text] [Related]
7. Acute infusion reactions to chemotherapeutic drugs: a single institute experience.
Muallaoglu S; Disel U; Mertsoylu H; Besen A; Karadeniz C; Taner Sumbul A; Abali H; Ozyilkan O
J BUON; 2013; 18(1):261-7. PubMed ID: 23613414
[TBL] [Abstract][Full Text] [Related]
8. Infusion reactions: diagnosis, assessment, and management.
Vogel WH
Clin J Oncol Nurs; 2010 Apr; 14(2):E10-21. PubMed ID: 20350882
[TBL] [Abstract][Full Text] [Related]
9. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience.
Polyzos A; Tsavaris N; Gogas H; Souglakos J; Vambakas L; Vardakas N; Polyzos K; Tsigris C; Mantas D; Papachristodoulou A; Nikiteas N; Karavokyros JG; Felekouras E; Griniatsos J; Giannopoulos A; Kouraklis G
Oncology; 2009; 76(1):36-41. PubMed ID: 19033714
[TBL] [Abstract][Full Text] [Related]
10. Best practices in multiple sclerosis: infusion reactions versus hypersensitivity associated with biologic therapies.
Namey M; Halper J; O'leary S; Beavin J; Bishop C
J Infus Nurs; 2010; 33(2):98-111. PubMed ID: 20228647
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab-associated infusion reactions: pathology and management.
Patel DD; Goldberg RM
Oncology (Williston Park); 2006 Oct; 20(11):1373-82; discussion 1382, 1392-4, 1397. PubMed ID: 17112000
[TBL] [Abstract][Full Text] [Related]
12. Review of hypersensitivity reactions to antineoplastic agents.
Cortijo-Cascajares S; Jiménez-Cerezo MJ; Herreros de Tejada A
Farm Hosp; 2012; 36(3):148-58. PubMed ID: 22484106
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin-associated hypersensitivity reactions: clinical presentation and management.
Hewitt MR; Sun W
Clin Colorectal Cancer; 2006 Jul; 6(2):114-7. PubMed ID: 16945166
[TBL] [Abstract][Full Text] [Related]
14. Hypersensitivity reactions to antineoplastic agents: an overview.
Syrigou E; Makrilia N; Koti I; Saif MW; Syrigos KN
Anticancer Drugs; 2009 Jan; 20(1):1-6. PubMed ID: 19342995
[TBL] [Abstract][Full Text] [Related]
15. Acute infusion reactions induced by monoclonal antibody therapy.
Maggi E; Vultaggio A; Matucci A
Expert Rev Clin Immunol; 2011 Jan; 7(1):55-63. PubMed ID: 21162650
[TBL] [Abstract][Full Text] [Related]
16. Biphasic and delayed hypersensitivity reactions.
Viale PH; Yamamoto DS
Clin J Oncol Nurs; 2010 Jun; 14(3):347-56. PubMed ID: 20529796
[TBL] [Abstract][Full Text] [Related]
17. Rapid desensitization for hypersensitivity reactions to chemotherapy agents.
Castells M
Curr Opin Allergy Clin Immunol; 2006 Aug; 6(4):271-7. PubMed ID: 16825867
[TBL] [Abstract][Full Text] [Related]
18. Infusion reactions triggered by monoclonal antibodies treating solid tumors.
Carney PH; Ollom CL
J Infus Nurs; 2008; 31(2):74-83. PubMed ID: 18344767
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab: adverse event profile and recommendations for toxicity management.
Thomas M
Clin J Oncol Nurs; 2005 Jun; 9(3):332-8. PubMed ID: 15973844
[TBL] [Abstract][Full Text] [Related]
20. Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment.
George TJ; Laplant KD; Walden EO; Davis AB; Riggs CE; Close JL; George SN; Lynch JW
J Support Oncol; 2010; 8(2):72-7. PubMed ID: 20464886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
